Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6916 to 6930 of 7691 results

  1. Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]

    Discontinued [GID-TA10634]

    Technology appraisal guidance
    Discontinued

  2. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued [GID-TA10585]

    Technology appraisal guidance
    Discontinued

  3. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued [GID-TA10492]

    Technology appraisal guidance
    Discontinued

  4. Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]

    Discontinued [GID-TA10628]

    Technology appraisal guidance
    Discontinued

  5. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued [GID-TA10134]

    Technology appraisal guidance
    Discontinued

  6. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued [GID-TA10590]

    Technology appraisal guidance
    Discontinued

  7. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued [GID-TA10922]

    Technology appraisal guidance
    Discontinued

  8. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued [GID-TA10857]

    Technology appraisal guidance
    Discontinued

  9. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued [GID-TA11209]

    Technology appraisal guidance
    Discontinued

  10. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued [GID-TA11210]

    Technology appraisal guidance
    Discontinued

  11. Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]

    In development [GID-TA11126] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development [GID-TA11157] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued [GID-TA11175]

    Technology appraisal guidance
    Discontinued

  14. Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

    Discontinued [GID-TA10494]

    Technology appraisal guidance
    Discontinued

  15. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued [GID-TA10309]

    Technology appraisal guidance
    Discontinued